breakthrough 

NEW MECHANISM TO FIGHT NEURODEGENERATION

FundaMental Pharma scientists discovered the antagonistic signaling of synaptic and extrasynaptic NMDA receptors and unraveled its molecular basis.

Mechanistic insight into the toxic actions of extrasynaptic NMDARs receptors guided the discovery of a new class of neuroprotectants: N/T Interface Inhibitors

Extrasynaptic NMDA receptor-mediated toxicity involves the NMDAR/TRPM4 interaction:

FundaMental Pharma develops NMDAR/TRPM4 interface inhibitors to prevent neuronal death:

Pipeline

our first indication 

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Amyotrophic Lateral Sclerosis, which is also known as Lou Gehrig Disease, is a rapidly progressive and detrimental neurodegenerative disease for which to date there is no cure or highly effective treatment available.

Disease-related facts

  • Most common motor neuron disease

  • World wide prevalence of ca. 4–5 /100,000

  • ~80–90% sporadic, ~10–20% hereditary forms

  • Fatal disease: average survival after diagnosis: 3–5 years

  • Symptoms progress from difficulties in movements to being wheel-chair bound and dependency on a ventilator

  • Can be associated with cognitive and behavioral changes

  • Available treatments with very little impact on disease progression


Targeting ALS with N/T Interface Inhibitors

the potential is huge 

FURTHER APPLICATIONS

Extrasynaptic NMDA-receptor-induced glutamate neurotoxicity is considered to be the mediator of neuronal death occurring in many neurodegenerative diseases. Among them are Huntington`s Disease, Stroke, and Alzheimer's Disease.

N/T Inferface Inhibitors – Broad Spectrum of Application